Discontinue its commercial organizations in the countries in scope

The partnership model will ensure continued access to Lundbeck’s medicines through trusted regional partners, while Lundbeck will discontinue its commercial organizations in the countries in scope, it states. In addition, Lundbeck will transition the majority of its current partner markets into the new partnerships with Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals.  

The phased transition to the partnership model is expected to be completed by 1 December, 2025 in all countries.

602 employees in the commercial organizations in the countries in scope

Lundbeck currently has 602 employees in the commercial organizations in the countries in scope. The majority of these in-country employees are expected to have the opportunity to get a new job with the local partners, who highly value their knowledge and experience.

“By reducing complexity and shifting resources to the markets and brands with the greatest growth potential, we are focusing capital to accelerate progress on our strategic priorities – most notably our growing late-stage pipeline in neuro-rare and neuro-specialty diseases,” says Charl van Zyl, President and CEO of Lundbeck. “I would like to thank all our employees in the countries in scope, whose outstanding work has allowed us to build strong foundations in the region.”